{"id":"W2415636816","doi":"10.1007/s10637-016-0367-2","title":"Phase I trial of dacomitinib, a pan-human epidermal growth factor receptor (HER) inhibitor, with concurrent radiotherapy and cisplatin in patients with locoregionally advanced squamous cell carcinoma of the head and neck (XDC-001)","year":2016,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre; University of Toronto","funders":"Pfizer","keywords":"Cisplatin; Epidermal growth factor receptor; Oncology; Medicine; Head and neck; Radiation therapy; Head and neck squamous-cell carcinoma; Internal medicine; Basal cell; Cancer research; Chemotherapy; Carcinoma; Head and neck cancer; Receptor; Surgery","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001970783,0.00172103,0.002463095,0.0005429452,0.0006581518,0.001448185,0.001223238,0.001371603,0.005119605],"category_scores_gemma":[0.001093912,0.0008777003,0.001730839,0.0007394715,0.001302254,0.001397467,0.0004605346,0.004189851,0.0008921904],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001937818,"about_ca_system_score_gemma":0.003044319,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.004029693,"about_ca_topic_score_gemma":0.01214499,"domain_scores_codex":[0.9995017,0.0002238951,0.00002155098,0.00009766535,0.00003398402,0.0001212432],"domain_scores_gemma":[0.9990897,0.0001251086,0.0001183449,0.00007480202,0.00005597494,0.0005360284],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8630871,0.04777519,0.005544371,0.0007614675,0.001643021,0.0001776183,0.0003491669,0.002489521,0.01607514,0.0004636418,0.00556246,0.05607131],"study_design_scores_gemma":[0.6535842,0.3313431,0.008066077,0.00003885879,0.0005743562,0.0001873846,0.0001063689,0.0007123425,0.002064966,0.0001922427,0.003101037,0.00002915781],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9862373,0.003196623,0.000394458,0.0007712491,0.0003069216,0.003036053,0.002184076,0.00008976991,0.003783488],"genre_scores_gemma":[0.9821104,0.003331674,0.001504102,0.001002321,0.0001792251,0.002588169,0.00444248,0.00004056026,0.004801106],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005119605,"threshold_uncertainty_score":0.01712674,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01778624658383064,"score_gpt":0.2729515223007116,"score_spread":0.255165275716881,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}